ArticleScientific reports2026
Metabolomic-driven prediction of the mutational status of healthy individuals with a family history of hereditary breast and ovarian cancer syndrome: the HRRmet study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Pathogenic variants (PVs) identified in genes involved in the DNA homologous recombination repair (HRR) mechanism are the main cause of hereditary breast and ovarian cancer syndrome (HBOC). The main objective of this study was to identify differential plasma metabolomic profiles associated with the HRR genotype in healthy individuals. Cascade testing was performed by Sanger sequencing in healthy carrier and noncarrier individuals with a familial history of HBOC. PVs associated with HRR genes (BRCA1, BRCA2, PALB2, ATM, CHEK2 and RAD51) were identified. Untargeted metabolomics of plasma samples was performed by liquid chromatography coupled with mass spectrometry. Predictive models were developed using a machine learning approach. Thirty-one metabolites were selected to create the global predictive model (accuracy 61.9%), whereas the gene-specific models had a better performance (accuracy > 80%) and were constructed with fewer metabolites. The present study is the first to characterize the phenotype associated with the HRR-deficient genotype in healthy individuals with a familial history of HBOC. Metabolomic profiles may be useful for differentiating carriers from noncarriers of PVs in the HRR genes, and therefore, with potential predictive capacity of the HRR germline mutational status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.